Drugs / Precise Vision Endothelial Keratoplasty (PVEK) Implant
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07325097 | Sep 2025 → Mar 2027 expected | Fuchs' endothelial dystrophy, bullous keratopathy | Precise Bio | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Precise Vision Endothelial Keratoplasty (PVEK) Implant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07325097 ↗ |
| Known as | PVEK | “PVEK is a tissue-engineered corneal endothelial implant intended to treat corneal endothelial dysfunction.” NCT07325097 ↗ |
| Modality | Cell therapy | “corneal endothelial cells (drug substance)” NCT07325097 ↗ |
| Route | Other | “is delivered into the anterior chamber during endothelial keratoplasty.” NCT07325097 ↗ |